FDA approves Regeneron’s Dupixent for bullous pemphigoid?

This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Regeneron Pharmaceuticals’ biologics license application (BLA) or supplemental BLA (sBLA) for Dupixent® (dupilumab) as a treatment for bullous pemphigoid by June 20, 2025, 11:59 PM ET. Otherwise, this market will resolve to "No." This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA, however a consensus of credible reporting may also be used.

How trading works

Polymarket uses a central limit order book (CLOB) model — you can buy or sell shares of any outcome at the current market price, or place limit orders at your target price. All positions are settled in USDC when the market resolves.

Resolution

Markets resolve through UMA's Optimistic Oracle. After the market closes, a proposer submits a resolution, followed by a 2-hour dispute window. If no dispute is raised, the resolution is accepted. Disputed markets go to UMA token holder vote.